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Abstract
Background: The role of germline mutations in BRCA1 and BRCA2 genes in the risk of the development of ovarian
cancer is clinically well established. BRCA1/2 testing seems to have increasing role in clinical management in
patients with advanced ovarian cancer who require treatment with poly(ADP-ribose) polymerase inhibitors.
Methods: Between 2002 – 2008, 125 consecutive patients with ovarian cancer were categorized as having three
founder mutations in the BRCA1 gene in Poland as: 5382insC [exon 20], 4153delA [exon 11.17], and 300 T > G [exon
5]. PFS (progression free survival) and OS (overall survival) were determined by Kaplan-Meier analysis with log rank
test, univariate comparisons, and multivariate regression analysis using Cox proportional hazards model.
Results: Of the 125 patients, the founder mutations of BRCA1 were reported in 17 patients (13.6 %). The median OS
was longer for BRCA mutated patients (not reached vs 35.6 months, p = 0.041). PFS was similar for both kinds of ovarian
cancer. In multivariate analysis, age ≥70 years, suboptimal surgery, and BRCA1 wild type were poor prognostic factors.
The BRCA1 mutation reduced the likelihood of death in ovarian cancer by 86 % (HR 0.14; CI: 0.032-0.650, p = 0.012).
Conclusion: In conclusion, we found better overall survival for ovarian cancer patients with BRCA1 germline mutations
in comparison with patients without these mutations (sporadic) ovarian cancer. Thus, BRCA1 germline mutations appear
to be an independent prognostic factor for ovarian cancer.
Keywords: Germline mutations of BRCA1, Ovarian cancer, Chemotherapy, Survival
Introduction
Ovarian cancer is the leading cause of death in women
from gynecological malignant diseases. The lifetime
probability of ovarian cancer in the general population is
approximately 1.6 %. This risk increases to 5 % for
women with one first-degree relative with ovarian cancer
and to 7.2 % for women with two or three relatives with
ovarian cancer [1].
BRCA1 and BRCA2 genes are high-penetrating with im-
portant roles during tumorigenesis. Both genes encode
proteins that interact with a machinery of recombination
of DNA or DNA repair pathways [2]. Twenty percent of
breast cancer has familial basis and approximately 5 % to
10 % of breast cancer is hereditary. Two-thirds of these
hereditary cancers occur in carriers with mutations of
BRCA1 or BRCA2 which are germline mutations [3].
Some preclinical studies have shown that BRCA1 appears
to be an important responding factor to both DNA-
damaging (platimun-compounds) and taxane-based
chemotherapy [4]. Molecularly, these anticancer agents
are to be as crucial modulators of BRCA-dependent
pathways, independently of detected BRCA1/2 muta-
tions defined germline or sporadic [5].
The BRCAness phenotype may be a result of defective
homologous recombination related to several mecha-
nisms, including epigenetic hypermethylation of the
BRCA1 promoter, somatic mutation of BRCA1/2, or loss
of function mutations in other homologous recombin-
ation orchestrating molecules. The complex profile of
the BRCAness phenotype correlates with responsiveness
* Correspondence: asynowiec@wim.mil.pl
1Department of Oncology, Military Institute of Medicine, 128 Szaserow Str.,
04-141 Warsaw, Poland
Full list of author information is available at the end of the article
© 2016 Synowiec et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Synowiec et al. Hereditary Cancer in Clinical Practice  (2016) 14:1 
DOI 10.1186/s13053-015-0044-z
to platinum and poly-ADP ribose polymerase (PARP) in-
hibitors [6]. On the other hand, there have been known
at least, two molecular mechanisms responsible for
chemotherapy resistance and recurrence of ovarian can-
cer such as 1.secondary mutations restoring BRCA1/2,
and 2.high levels of PARP, Fanconi anemia proteins and
P53 [7, 8]. Determination of the BRCA1/2 status may be
a relevant clinical biomarker both for survival prognosis
and prediction both for response or resistance to chemo-
therapy in sporadic ovarian cancer [9, 10].
BRCA mutations may have impact on better survival
of patients with ovarian cancer when compared with
those without mutations. Several studies have investi-
gated the possible effects of BRCA1 mutation on clinical
and pathologic characteristics defined by earlier age of
onset in any mutation carriers with the possible better
response to platinum-based chemotherapy, but results of
these studies were inconclusive. Some of these studies
have demonstrated longer survival in epithelial invasive
ovarian cancer patients [11, 12] who are BRCA1 muta-
tion carriers in comparison with noncarriers, but other
investigators did not find a survival benefit in BRCA1
mutation carriers [13–15]. Recently reported results
have revealed that after 3 years since the ovarian cancer
diagnosis, the presence of a BRCA1 or BRCA2 mutation
was associated with a clinically better prognosis (HR
0.68; 95 % CI: 0.48–0.98, p = 0.03), which has not been
sustained 10 years after the diagnosis of ovarian cancer
(HR 1.00; 95 % CI: 0.83–1.22, p = 0.90) [16, 17].
The aim of our study was to assess clinical features
and treatment outcomes in ovarian cancer patients,
having a founder mutation in BRCA1 gene in com-




A consecutive series of 125 patients with ovarian can-
cer diagnosed and treated at the Military Institute of
Medicine in Warsaw, Poland, between 2002–2008 was
studied. All patients underwent surgery defined as rad-
ical, optimal tumor debulking with residual disease <
1 cm, or suboptimal as residual disease > 1 cm. The
pathology reports were classified as epithelial ovarian
cancer serous, endometrioid, mucinous, clear cell,
mixed, or unspecified. Chemotherapy was used in all
patients. Mutation analysis was performed in all en-
rolled patients. The study protocol was approved by
the local Ethics Committee (The Resolution of The
Bioethics Committee of Military Institute of Medicine
at Warsaw, No 48/WIM/2008 data November, 19th
2008), and written informed consent was obtained
from all participants of the study.
Chemotherapy regimen
The first line chemotherapy consisted of 6 courses. The
first version of chemotherapy regimen consisted of
135 mg/m2 of intravenous infusion paclitaxel over 24-h
on day 1 followed by 75 mg/m2 of intravenous infusion
cisplatin on day 2. The second version of chemotherapy
regimen consisted of 175 mg/m2 of intravenous infusion
paclitaxel over 3-h on day 1 followed by AUC6 according
to Calvert formula of intravenous 30-min infusion carbo-
platin on day 2. Standard premedication (dexamethasone
20 mg, ranitidinum 50 mg, clemastinum 2 mg) was given
intravenously to prevent hypersensitivity reaction to pacli-
taxel. Treatments were administered every 3 weeks. The
third version of chemotherapy was based upon carbopla-
tin AUC5 according to Calvert formula of intravenous 30-
min infusion. The fourth version of treatment was given
as neoadjuvant triple chemotherapy regimen based upon
paclitaxel (175 mg/m2 over 3-h intravenously), carboplatin
(AUC5 intravenously), and caelyx (20 mg/m2 intraven-
ously) or epirubicin (50 mg/m2 intravenously) which was
administered for three courses before debulking surgery
with further continuation of standard chemotherapy with
paclitaxel and carboplatin in mentioned doses up to total
number of six courses. The fifth version of chemotherapy
was a regimen based upon combination of gemcitabine
(1000 mg/m2 intravenously on days 1,8 every 21 days) and
cisplatin (75 mg/m2 intravenously on day 1 every 21 days)
given as the primary chemotherapy as well.
Mutational analysis
High-molecular-weight DNA was isolated from periph-
eral blood leukocytes by nonenzymatic and rapid
method described by Lahiri and Nurnberger [18]. Muta-
tion analysis was performed for three common in Poland
founder mutations in BRCA1 (5382insC – exon 20;
4153delA – exon 11.17) by a multiplex allele-specific
polymerase chain reaction (PCR) assay. 300 T > G –
exon 5 mutation generates a novel restriction enzyme
site. This mutation can be detected after digesting amp-
lified DNA with Ava II. To show the different BRCA1 al-
leles, the PCR products were subjected to horizontal
electrophoresis in a 2.0 % agarose gel and stained with
ethidium bromide. We analyzed samples of all enrolled
patients [19].
Statistical analysis
Demographic data are shown as median or mean with
standard deviation (SD) and 95 % confidence interval
(CI). Relationships between categorical variables were
assessed using the Chi-square test, Yates-corrected Chi-
square test or Mann–Whitney U test. Progression-free
survival (PFS) was calculated from the start date of
chemotherapy to the first evidence of treatment failure.
Overall survival (OS) was defined as the time interval
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between the date of starting chemotherapy to death of
any cause. PFS and OS were estimated using the
Kaplan-Meier methods and differences in survival were
compared by using log-rank test. On univariate com-
parisons of survival between groups, statistical signifi-
cance was assessed using the Cox-Mantel test.
Multivariate regression analyses were performed using
the Cox proportional hazards model. A p value of <0.05
was considered statistically significant. For calcula-




The study population involved a series of 125 consecu-
tive patients with ovarian cancer treated primary surgi-
cally and further chemotherapeutically. Table 1 shows
patient characteristics. The patients’ age ranged from 28
to 85 years (median, 55 years). Most patients were in ad-
vanced stage ovarian cancer (III and IV stages, 101/125:
80.8 %). More than half of patients were diagnosed
pathologically with serous ovarian cancer. Standard
chemotherapy was given to participated patients in this
study with exception of one patient received gemcitabine
combined with cisplatin as the primary chemotherapy.
Three founder mutations (5382insC – exon 20;
4153delA – exon 11.17; 300 T > G – exon 5) dominating
in Poland were tested. Founder mutations of the BRCA1
gene were noted with the rate of 13.6 %. The most fre-
quent (9.6 %) mutation was in exon 20 (5382insC).
Table 2 shows the comparative distribution of founder
mutations of BRCA1 in ovarian cancer patients.
Table 3 presents clinical and pathological ovarian cancer
characteristics with the BRCA1 gene status. Younger
patients with ovarian cancer were seen among BRCA1
mutation carriers in comparison with noncarriers (median
age 47 vs 56, respectively, p = 0.004).
Progression free survival analysis incorporated the status
of the BRCA1 gene and other clinical variables
On univariate analysis for PFS, patients with advanced
stage, serous histology, nonoptimal debulking surgery
with residual tumor > 1 cm, and without paclitaxel in the
chemotherapy regimen correlated with worse PFS.
BRCA1 gene status was not a significant factor for PFS.
Detailed results of univariate and multivariate analyses
are shown in Table 4. The FIGO stage, serous histology,
optimal debulking surgery, and chemotherapy with pac-
litaxel combined with platinum compound were signifi-
cant prognostic factors for PFS. The status of BRCA1
was not of clinical value as prognostic factor after using
multivariate analysis for PFS.
Table 1 Patient characteristics
Number of patients n = 125
Median (range) age at diagnosis in years 55 (28–85)
Performance status WHO:
▪ 0 15.2 % (19/125)
▪ 1 77.6 % (97/125)
▪ 2 7.2 % (9/125)
BSA (m2) 1.69 (95 % CI; 1.65–1.72)
FIGO stage:
▪ I 11.2 % (14/125)
▪ II 8.0 % (10/125)
▪ IIIA 5.6 % (7/125)
▪ IIIB 7.2 % (9/125)
▪ IIIC 56.0 % (70/125)
▪ IV 12.0 % (15/125)
Chemotherapy regimen:
▪ Paclitaxel/cisplatin 43.2 % (54/125)
▪ Paclitaxel/carboplatin/ caelyx 8.8 % (11/125)
▪ Paclitaxel/carboplatin 36.8 % (46/125)
▪ Carboplatin 8.8 % (11/125)
▪ Paclitaxel/carboplatin/epirubicin 1.6 % (2/125)
▪ Gemcitabine/ cisplatin 0.8 % (1/125)
Type of histology:
▪ Serous 54.4 % (68/125)
▪ Endometrioid 26.4 %(33/125)
▪ Mucinous 7.2 % (9/125)
▪ Clear cell 4.0 % (5/125)
▪ Mixed 2.4 % (3/125)
▪ Unspecified 5.6 % (7/125)
Grading:
▪ 1 3.2 % (4/125)
▪ 2 32.8 % (41/125)
▪ 3 23.2 % (29/125)
▪ Unspecified 40.8 % (51/125)
Primary surgery:
▪ Radical 19.2 % (24/125)
▪ Optimal (<1 cm) 42.4 % (53/125)
▪ Suboptimal (>1 cm) 38.4 % (48/125)
Table 2 Distribution of founder mutations of the BRCA1 gene in
ovarian cancer patient
Germline mutation All ovarian cancer (n = 125)
5382insC [exon 20] 12/125 (9.6 %)
300 T > G [exon 5] 3/125 (2.4 %)
4153delA [exon 11.17] 2/125 (1.6 %)
All mutations 17/125 (13.6 %)
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Overall survival analysis incorporated the status of the
BRCA1 gene and other clinical variables
On univariate analysis for OS (Table 5), we show that
age at ovarian cancer onset ≥70 years, advanced stage,
serous histology, suboptimal surgery, and use of chemo-
therapy regimen without paclitaxel are related to shorter
OS. Interestingly, BRCA1 status appeared to be of clin-
ical value as a prognostic factor for OS in ovarian cancer
patients. Carriers of any mutation of the BRCA1 gene
with ovarian cancer had better survival at two years in
comparison with noncarriers. Figure 1 presents OS in
patients with ovarian cancer stratified by BRCA1 sta-
tus with median not reached in carriers of BRCA1
mutations vs median of 35.6 months for noncarriers
(p = 0.041). In multivariate analysis (Table 5), age ≥
70 years, suboptimal surgery and expression of wild
type of the BRCA1 gene correlate with poor prognosis
for OS. BRCA1 germline mutations reduced by 86 %
likelihood of death in our ovarian cancer patients (HR
0.14 [CI: 0.032–0.650], p = 0.012).
Discussion
Our results found the total rate of BRCA1 mutations
was 13.6 % in 125 ovarian cancer patients. This result is
in accordance with other previously published studies in
the Polish population with germline mutations in BRCA1
and BRCA2 in 13.5 % and 13.9 % of patients, respectively
[20, 21]. We also show that BRCA1 germline mutations
are associated with good prognosis for patients with ovar-
ian cancer and OS was better for carriers of BRCA1 muta-
tions (HR 0.14, 95 % CI: 0.032–0.650, p = 0.012) than for
noncarriers. This observation is in accordance with results
of other authors, for example, Rubin et al. [22] for the first
time determined that ovarian cancer associated with
BRCA1 mutations had a more favorable clinical course,
and it was confirmed by other studies in which this advan-
tage in survival of mutation carriers was reported to be an
independent protective factor [23].
Here we report that PFS assessed both on univariate
and on multivariate analyses (BRCA1 mutations vs
BRCA1 wild type, median 21.5 months vs 14.6 months,
p = 0.58, respectively) show a slight favor with predictive
value for patients with mutated BRCA1 but without stat-
istical significance. We present that FIGO stage, serous
histologic type, primary debulking surgery and chemo-
therapy based upon combination of platinum compound
with paclitaxel, are typical clinical variables that correlate
with PFS. Among 71 Jewish patients with ovarian cancer,
22 had BRCA1 three germline mutations and one trun-
cating mutation, and 12 had BRCA2 truncating muta-
tions vs 37 patients with sporadic ovarian cancer.
Overall survival was improved in patients with mutated
forms of BRCA in comparison with sporadic ovarian
cancer patients (91 months vs 54 months, respectively;
p = 0.046). In accordance with our results, the authors
showed that patients with BRCA mutations had slightly
longer disease free survival but not statistically signifi-
cant (49 months vs 19 months, respectively; p = 0.16)
[24]. Tan et al. [25] coined the term of a clinical syn-
drome of BRCAness which relies on better prognosis for
response rate after first- line chemotherapy and at subse-
quent recurrences, overall survival, serous histology (but
not necessary), and TFI (treatment-free interval defined as
the time between each line of treatment calculated from
the date of the last course of the previous chemotherapy
to the date of the first cycle of the next chemother-
apy). In ovarian cancer patients with BRCA mutations
the median TFI for three lines of chemotherapy was
significantly longer than in sporadic ovarian cancer pa-
tients (first-line, p < 0.001; second-line, p < 0.015; third-
line, p = 0.002, respectively). The median overall survival
for BRCA-positive ovarian cancer patients was better than
in controls (from the time of diagnosis 8.4 years vs
2.9 years, respectively; p < 0.002) [25, 26]. Gallagher et al.
[27] reported in a group of 110 patients (36 with three
Table 3 Clinical and pathological ovarian cancer characteristics
determined by the BRCA1 gene status






Median (range) age at
diagnosis in years
56 (28–85) 47 (39–70) −2.859a 0.004
Performance status WHO:
▪ 0 15 4
▪ Other 93 13 0.44b 0.51
FIGO stage:
▪ Early (I, II) 22 3
▪ Advanced (III,IV) 86 14 0.07b 0.95
Chemotherapy regimen:
▪ With paclitaxel 97 16
▪ Without paclitaxel 11 1 0.01b 0.91
Chemotherapy regimen:
▪ With cisplatin 47 8
▪ With carboplatin 61 9 0.1c 0.75
Type of histology:
▪ Serous 57 11
▪ Other 51 6 0.84c 0.36
Grading:
▪ 1 and 2 38 7
▪ 3 and unspecified 70 10 0.23c 0.63
Primary surgery:
▪ Optimal (<1 cm) 68 9




Synowiec et al. Hereditary Cancer in Clinical Practice  (2016) 14:1 Page 4 of 8
germline mutations of BRCA genes (20 BRCA1 muta-
tions, 16 BRCA2 mutations) vs 74 controls) that ovarian
cancer patients with BRCA mutations had better sur-
vival (median not reached vs 67.8 months for controls,
respectively; p = 0.02). The multivariate analysis sus-
tained crucial role of BRCA mutations in overall survival
prognosis (HR 0.36; 95 % CI 0.14–0.93) but disease-free
survival was not significantly different between BRCA mu-
tations and control ovarian cancer patients (median
26.9 months vs 24.0 months, respectively; p = 0.30).
In our study, the age at the onset of ovarian cancer for
BRCA1 wild type was almost 10 years postponed than in
carriers of BRCA1 mutations (median 56 years vs
47 years, respectively, p = 0.004). Thigpen et al. [28] de-
cided to determine major prognostic factors in 2123
ovarian cancer patients who were studied in the six
GOG (Gynecologic Oncology Group) clinical trials. It
turned out that only three factors had impact on progno-
sis for overall survival of the entire investigated popula-
tion, i.e., age, volume of residual disease, and performance
status. Based upon the results of studied patients, elder
patients with ovarian cancer (>69 years) had poorer sur-
vival. Therefore, age seems to have indirect roles in better
survival of patients with mutated BRCA1 through better
response to chemotherapy, better tolerance of such a ther-
apy without other health problems which typically are as-
sociated with elder patients. But on the other hand, the
second-line chemotherapy due to relapsed ovarian cancer
could be used in elder patients after detailed assessment
of performance status rather than making-decision based
primarily on the age [29].
Malignant diseases are the final results of incorrect in-
teractions between immune-surveillance in a healthy or-
ganism and unrestricted proliferation of a small portion
of cells that constitute a solid tumor or leukemia. The
fundamental process that is primarily responsible for
tumorigenesis embraces changes in the DNA sequences
of the genomes of malignant cells. Recently accumulat-
ing knowledge clearly shows that detection cancer gen-
ome structural changes at the levels of DNA sequences
(mainly somatic mutations) and epigenetic alterations
lead to improper functions in cells that constantly become
malignant. This dynamic process defines cancer as an evo-
lutionary entity determining highly probabilistic events
providing finally advanced malignant disease [30]. Natur-
ally occurring during malignant progression, genome
Table 4 Univariate and multivariate analyses for PFS of ovarian
cancer
Univariate analysis
Variable n (%) Median (months) p value
Age:
<70 118 (94.4 %) 10.4 0.51
≥70 7 (5.6 %) 16.0
Performance status WHO:
▪ 0 19 (15.2 %) 14.7 0.06
▪ Other 106 (84.8) 21.4
FIGO stage:
▪ Early (I,II) 24 (19.2 %) NR <0.001
▪ Advanced (III, IV) 101 (80.8 %) 13.4
Chemotherapy regimen:
▪ With paclitaxel 113 (90.4 %) 16.8 0.032
▪ Without paclitaxel 12 (9.6 %) 10.3
Chemotherapy regimen:
▪ With cisplatin 55 (44.0 %) 23.0 0.24
▪ With carboplatin 70 (56.0 %) 13.5
Type of histology:
▪ Serous 68 (54.4 %) 13.2 <0.001
▪ Other 57 (45.6 %) 34.8
Grading:
▪ 1 and 2 45 (36.0 %) 16.0 0.40
▪ 3 and unspecified 80 (64.0 %) 14.6
Primary surgery:
▪ Optimal (<1 cm) 77 (61.6 %) 24.7 <0.001
▪ Suboptimal (>1 cm) 48 (38.4 %) 11.0
BRCA1 status:
▪ Wild type 108 (86.4 %) 14.6 0.58
▪ Germline mutation 17 (13.6 %) 21.5
Multivariate analysis
Variable HR (95 % CI) p value
FIGO stage:
▪ Early (I,II) 0.21 (0.071 – 0.634) 0.006
▪ Advanced (III, IV)
Chemotherapy regimen:
▪ With paclitaxel 0.46 (0.242 – 1.020) 0.034
▪ Without paclitaxel
Type of histology:
▪ Serous 0.55 (0.318 – 0.916) 0.027
▪ Other
Primary surgery:
▪ Optimal (<1 cm) 0.54 (0.308 – 0.804) 0.011
▪ Suboptimal (>1 cm)
Table 4 Univariate and multivariate analyses for PFS of ovarian
cancer (Continued)
BRCA1 status: NG NS
▪ Wild type
▪ Germline mutation
NG not given, NR not reached, NS statistically not significant
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changes and epigenetic alterations seem to have impact
on detection of molecular abnormalities with clinical use-
fulness at a bed in oncology ward. TCGA (The Cancer
Genome Atlas) project is a well-know initiative to estab-
lish a series of somatic mutations and epigenetic
alterations in human cancer samples in relation to clinical
data. Analyses performed in 489 ovarian cancer samples
(mainly high-grade serous ovarian adenocarcinoma) re-
vealed changes in expression of mRNA, noncoding RNA,
methylation of promoter of many genes, and changed
DNA copy numbers. The most important gene mutations
were ascribed to P53 detected in 96 % of investigated sam-
ples. Other low prevalent with statistical relevance aberra-
tions in the form of somatic mutations were noted in such
genes as NF1, BRCA1, BRCA2, RB1 and CDK12. In 168
genes, the authors detected promoter methylation alter-
ations and prognosis for survival was performed in pa-
tients with BRCA mutations and CCNE1 aberrations [31].
Based on a cohort of 316 ovarian cancer patients taken
from TCGA, 77.8 % had BRCA1/2 wild type, 8.5 % had
germline mutations, 3.1 % had somatic mutations, and
10.4 % had BRCA1 hypermethylation. Detailed analyses
showed that the only prognostic factor for OS in ovarian
cancer was mutated BRCA2 (HR 0.33; 95 % CI: 0.16–0.69,
p = 0.003). Taking into account platinum-based chemo-
therapy efficacy, mutated BRCA2 gene had significantly
longer PFS (HR 0.40; 95 % CI: 0.22–0.74, p = 0.004) [32].
Also, Hyman et al. [33] reported that better survival was
seen in patients carrying BRCA2 mutations [HR 0.20;
95 % CI 0.06–0.65, p = 0.007] compared with either
BRCA1 carriers [HR 0.70; 95 % CI 0.36–1.38, p = 0.31] or
noncarriers. The presented results are surprising, espe-
cially in the context of many published studies showing
prognostic role of germline mutations of BRCA1 gene. It
seems that patient selection through a specific definition
of primary response to adjuvant chemotherapy or variety
in stage distribution will play a crucial role in the process
of analysis and interpretation of collected results, but
further studies should be planned as randomized and con-
trolled with statistically well-founded number of partici-
pating patients. Some commentaries on the potential role
of BRCA2 mutations as a real prognostic factor in ovarian
cancer patients show such a particular role of patient
selection and differences in surgical and oncologic
managements [34].
Conclusions
To summarise, our findings confirm previous reports
that improved overall survival associated with BRCA1
mutations carried in ovarian cancer patients. Both uni-
variate and multivariate analyses show that the BRCA
gene status dychotomizes ovarian cancer patients to bet-
ter and worse prognosis for overall survival (BRCA1
germline mutations constitute better prognosis than
BRCA1 wild type). The most important limitation of our
study is a small number of patients (125 patients, 17
with germline mutations of BRCA1 and 108 controls).
Moreover, we focused only on three BRCA1 germline
mutations typical for the Polish population that reflects
Table 5 Univariate and multivariate analyses for OS of ovarian
cancer
Variable n (%) Median (months) p value
Age:
<70 118 (94.4 %) 46.0 0.022
≥70 7 (5.6 %) 14.8
Performance status WHO:
▪ 0 19 (15.2 %) NR 0.28
▪ Other 106 (84.8) 36.2
FIGO stage:
▪ Early (I,II) 24 (19.2 %) NR 0.003
▪ Advanced (III, IV) 101 (80.8 %) 33.3
Chemotherapy regimen:
▪ With paclitaxel 113 (90.4 %) 46.1 0.035
▪ Without paclitaxel 12 (9.6 %) 16.6
Chemotherapy regimen:
▪ With cisplatin 55 (44.0 %) 50.5 0.24
▪ With carboplatin 70 (56.0 %) 32.3
Type of histology:
▪ Serous 68 (54.4 %) 33.2 0.047
▪ Other 57 (45.6 %) NR
Grading:
▪ 1 and 2 45 (36.0 %) 49.8 0.53
▪ 3 and unspecified 80 (64.0 %) 35.6
Primary surgery:
▪ Optimal (<1 cm) 77 (61.6 %) 51.8 0.028
▪ Suboptimal (>1 cm) 48 (38.4 %) 30.0
BRCA1 status:
▪ Wild type 108 (86.4 %) 35.6 0.041
▪ Germline mutation 17 (13.6 %) NR
Multivariate analysis
Variable HR (95 % CI) p value
Age:
<70 0.15 (0.053 – 0.417) <0.001
≥70
Primary surgery:
▪ Optimal (<1 cm) 0.39 (0.205 – 0.715) 0.003
▪ Suboptimal (>1 cm)
BRCA1 status:
▪ Germline mutation 0.14 (0.032 – 0.650) 0.012
▪ Wild type
NR not reached
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low frequency such patients among consecutive patients
visiting an oncologist. However, our results are consist-
ent with other reports discussed above.
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